Polyrizon Launches GMP Manufacturing for U.S. Clinical Trial

Polyrizon has completed GMP manufacturing of clinical trial material for its lead intranasal hydrogel after two prior development batches demonstrated batch-to-batch consistency and stability, positioning the preclinical company to initiate a U.S. study later this year.

The company partnered with Eurofins CDMO AmatsiAquitaine to produce the batch under applicable GMP standards. The material will supply an upcoming clinical program built around Polyrizon’s hydrogel nasal spray platform designed to form a temporary barrier in the nasal cavity against airborne allergens and viruses. The manufacturing step follows development-scale production runs that established reproducibility and stability, important prerequisites for regulatory submissions and first-in-human testing.

Operationally, this is a move to de-risk CMC ahead of clinical entry and to compress timelines by locking in a commercial-grade process before proof-of-concept. For a barrier-forming, device-like product where systemic exposure is minimal, the regulatory emphasis shifts toward quality, consistency, device performance, and real-world use profiles rather than complex pharmacology. Outsourcing to a global CDMO with nasal spray and fill-finish expertise is a signal that Polyrizon is prioritizing supply reliability and scalability early, rather than iterating on formulation post-Phase 1.

The implications for stakeholders are immediate. Sites could see a low operational burden study: no cold chain, straightforward storage, and rapid administration with standard device accountability. If the initial indication centers on allergens, seasonality will dictate site selection and activation, and endpoints may lean on symptom scores, rescue medication use, and controlled exposure models, which favor networks with challenge unit capabilities. If the program targets respiratory viruses, sponsors and CROs face a higher evidence bar and more complex trial logistics, including event-driven designs, incident rate variability, and adherence monitoring—areas where decentralized follow-up and ePRO can help but will require tight protocol discipline to avoid signal dilution. Regulators will key in on product classification. A barrier hydrogel positioned as a medical device could pursue a De Novo or 510(k) path contingent on predicate and intended use; any progression toward intranasal delivery of active pharmaceutical ingredients from the same platform would shift requirements toward combination-product oversight, expanding the CMC and human factors workload.

For CDMOs and device vendors, the program adds demand for nasal spray components, human factors validation, and packaging that supports adherence. CROs with respiratory, allergy, and human factors expertise may find an opening if Polyrizon scales quickly into multi-center studies. For patients, the promise is convenience, but outcomes will hinge on consistent use in real-world settings; adherence and training will be as determinative as formulation.

The next milestones to watch are U.S. regulatory filings that clarify whether the study proceeds under an IDE- or IND-aligned framework, protocol details that define primary endpoints and population, and any shelf-life claims from stability work that determine distribution flexibility. Risks include classification uncertainty, the evidentiary threshold for prevention claims—especially for viral indications—and the challenge of demonstrating meaningful, durable benefit in everyday use. If Polyrizon can translate clean manufacturing execution into crisp trial design and operational simplicity at sites, the platform could test the market’s appetite for device-forward respiratory prevention strategies at a time when payers and regulators are increasingly focused on pragmatic, reproducible outcomes.

Source link: https://www.globenewswire.com/news-release/2026/03/10/3252694/0/en/Polyrizon-Announces-GMP-Manufacturing-of-Clinical-Trial-Material-CTM-with-Eurofins-CDMO-AmatsiAquitaine-S-A-S-for-Planned-U-S-Clinical-Study.html